[68Ga]Ga-AUNP-12 PET显像评估临床前及首次人体研究中的PD-L1状态
研究开发了新型肽类PET示踪剂[68Ga]Ga-AUNP-12用于PD-L1显像,在细胞系和动物模型中验证其特异性,并在健康志愿者和癌症患者中完成首次人体评估;结果显示该示踪剂可灵敏检测PD-L1表达及其动态变化,能有效指导免疫治疗,且用于人体是安全的。
要点
- [68Ga]Ga-AUNP-12的放射化学产率为71.7±8.2%,摩尔活度和放射化学纯度令人满意。
- 注射后60分钟B16F10肿瘤摄取为6.86±0.71% ID/g,肿瘤与肌肉比值为6.83±0.36。
- 在肺腺癌和食管鳞状细胞癌(OSCC)患者中,肿瘤摄取与高PD-L1表达强相关。
核心结论
- [68Ga]Ga-AUNP-12在临床前和首次人体研究中成功开发为PD-L1特异性PET显像示踪剂。
研究设计与样本
- 研究进行了[68Ga]Ga-AUNP-12的放射合成,在PANC02、CT26和B16F10细胞系上进行细胞摄取和结合实验。
- 使用临床前模型研究其生物分布、显像能力和药代动力学,并用干扰素-γ(IFN-γ)建立高PD-L1表达的动物模型进行靶向PET显像和PD-L1阻断治疗疗效评估。
- 在健康志愿者和癌症患者中进一步评估PD-L1显像、辐射剂量学、安全性和生物分布。
主要发现
- 体外和体内动物研究显示[68Ga]Ga-AUNP-12 PET显像在评估PD-L1表达方面具有高特异性。
- [68Ga]Ga-AUNP-12的放射化学产率为71.7±8.2%,摩尔活度和放射化学纯度令人满意。
- 注射[68Ga]Ga-AUNP-12后60分钟B16F10肿瘤显影,肿瘤摄取为6.86±0.71% ID/g,肿瘤与肌肉比值为6.83±0.36。
- [68Ga]Ga-AUNP-12 PET显像可灵敏检测CT26肿瘤异种移植模型中IFN-γ治疗调控的PD-L1动态变化,并相应有效指导免疫治疗。
- 关于辐射剂量学,[68Ga]Ga-AUNP-12用于人体是安全的;首次人体研究发现其可通过肾脏排泄快速从血液和其他非特异性器官清除,在临床框架中形成清晰的显像对比。
关键数值与推荐
- 放射化学产率为71.7±8.2%,摩尔活度和放射化学纯度令人满意。
- B16F10肿瘤在注射后60分钟肿瘤摄取为6.86±0.71% ID/g,肿瘤与肌肉比值为6.83±0.36。
临床怎么用
- [68Ga]Ga-AUNP-12 PET显像可灵敏检测PD-L1动态变化并相应有效指导免疫治疗,用于人体是安全的。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: PD-L1 PET imaging, as a non-invasive procedure, can perform a real-time, dynamic and quantitative analysis of PD-L1 expression at tumor sites. In this study, we developed a novel peptide-based PET tracer, [68 Ga]Ga-AUNP-12, for preclinical and first-of-its-kind imaging of PD-L1 expression in patients. METHODS: Radiosynthesis of [68 Ga]Ga-AUNP-12 was conducted. Assays for cellular uptake and binding were conducted on the PANC02, CT26, and B16F10 cell lines. Preclinical models were used to investigate its biodistribution, imaging capacity, and pharmacokinetics. Furthermore, interferon-γ (IFN-γ) was used for development of an animal model with high PD-L1 expression for targeted PET imaging and efficacy evaluation of PD-L1 blocking therapy. In healthy volunteers and cancer patients, the PD-L1 imaging, radiation dosimetry, safety, and biodistribution were further evaluated. RESULTS: In vitro and in vivo animal studies showed that [68 Ga]Ga-AUNP-12 PET imaging displayed a high specificity in evaluating PD-L1 expression. The radiochemical yield of [68 Ga]Ga-AUNP-12 was 71.7 ± 8.2%. Additionally, its molar activity and radiochemical purity were satisfactory. The B16F10 tumor was visualized with the tumor uptake of 6.86 ± 0.71% ID/g and tumor-to-muscle ratio of 6.83 ± 0.36 at 60 min after [68 Ga]Ga-AUNP-12 injection. Furthermore, [68 Ga]Ga-AUNP-12 PET imaging could sensitively detect the PD-L1 dynamic changes in CT26 tumor xenograft models regulated by IFN-γ treatment, and correspondingly can effectively guide immunotherapy. Regarding radiation dosimetry, [68 Ga]Ga-AUNP-12 is safe for human use. The first human study found that [68 Ga]Ga-AUNP-12 can be rapidly cleared from blood and other nonspecific organs through the kidney excretion, leading to form a clear imaging contrast in the clinical framework. The specificity of [68 Ga]Ga-AUNP-12 was validated and tumor uptake strongly correlated with the high PD-L1 expression in patients with lung adenocarcinoma and oesophageal squamous cell carcinoma (OSCC). CONCLUSION: [68 Ga]Ga-AUNP-12 was successfully developed as a PD-L1-specific PET imaging tracer in preclinical and first-in-human studies.
引用
- Zhou M, Xiang S, Zhao Y, et al. [68Ga]Ga-AUNP-12 PET imaging to assess the PD-L1 status in preclinical and first-in-human study. Eur J Nucl Med Mol Imaging. 2023. PMID: 37759096. doi:10.1007/s00259-023-06447-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。